Rumor reaches us that another new biotech company, called Fortis Therapeutics, is to be focused (at least initially) on possible new forms of treatment for late stage prostate cancer.
The company’s primary strategic asset appears to be a currently unidentified agent developed at the University of California, San Francisco. All we know at this time is that this is a product for the potential treatment of men with castration-resistant prostate cancer (CRPC) progressing after treatment with drugs like abiraterone acetate (Zytiga) and enzalutamide (Xtandi), but not focused on treatment of men with the AR-V7 mutation.
For more information, we refer readers to articles in the San Diego Union-Tribune and on the Endpoints biotech news site.
But be warned, new products like this move into early development all the time. Many of them never make it into Phase III clinical trials. Even fewer actually get approved by the U.S. Food and Drug Administration. A product like this is probably at least 5 to 7 years away from completion of a Phase III clinical trial — and that is if everything were to move at lightening speed.
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, Fortis |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply